argenx SE (NASDAQ:ARGX) Given Consensus Recommendation of “Moderate Buy” by Analysts

argenx SE (NASDAQ:ARGX) has been given an average rating of “Moderate Buy” by the twenty-two research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $658.39.

ARGX has been the subject of a number of analyst reports. JMP Securities increased their target price on argenx from $606.00 to $696.00 and gave the stock a “market outperform” rating in a research note on Tuesday, January 14th. Baird R W cut argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. Robert W. Baird lowered shares of argenx from an “outperform” rating to a “neutral” rating and boosted their target price for the stock from $515.00 to $650.00 in a research report on Friday, November 1st. Truist Financial reiterated a “buy” rating and issued a $700.00 price target (up previously from $660.00) on shares of argenx in a report on Tuesday, January 14th. Finally, JPMorgan Chase & Co. upped their target price on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th.

argenx Trading Down 1.8 %

NASDAQ:ARGX opened at $639.41 on Tuesday. argenx has a 12-month low of $349.86 and a 12-month high of $678.21. The stock’s 50 day simple moving average is $640.16 and its 200-day simple moving average is $583.65. The firm has a market cap of $38.85 billion, a P/E ratio of -726.60 and a beta of 0.58.

Hedge Funds Weigh In On argenx

Large investors have recently modified their holdings of the company. FMR LLC boosted its holdings in argenx by 35.9% in the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after acquiring an additional 1,265,486 shares during the period. Lord Abbett & CO. LLC acquired a new stake in argenx during the 3rd quarter valued at $88,339,000. Point72 Asset Management L.P. purchased a new stake in argenx during the 4th quarter worth $91,013,000. Allspring Global Investments Holdings LLC lifted its holdings in argenx by 38,152.3% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company’s stock worth $89,391,000 after buying an additional 143,834 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in argenx by 184.7% in the 4th quarter. Marshall Wace LLP now owns 191,553 shares of the company’s stock valued at $117,805,000 after buying an additional 124,271 shares during the last quarter. 60.32% of the stock is currently owned by hedge funds and other institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.